Chimeric Therapeutics is trading A$0.01 (-10.00%) amid pressure after August 19 news that CHM-2101 trial enrollment ceased following dose-limiting toxicities.
- No new company-specific announcement explaining the August 31, 2026 decline was identified.
- The strategic-review process was scheduled to close August 31, while funding discussions remained incomplete and uncertain.
- The stock has declined across six of the prior seven provided sessions.